S_ary The use of chemotherapy as a form of primary treatment for breast cancer is increasing and, as a result, more resection specimens contain tumours which have been exposed to cytotoxic drugs. We have studied the effects of chemotherapy on the tumour morphology and various biological features of breast carcinoma in a group of 35 patients. These were a group who responded to treatment in a clinical study of the use of primary chemotherapy designed to reduce tumour bulk prior to surgery. Characteristic morphological changes, temporally related to the administration of cytotoxic agents, are seen. The malignant cells become enlarged with vacuolated cytoplasm and vesicular nuclei containing prominent nucleoli; occasionally the nuclei were angular and hyperchromatic. These features are interpreted as degenerative in nature. In 15 cases sufficient material was present in the pretreatment biopsies to compare the grade of the tumours before and after chemotherapy: changes were found in six tumours. Cytotoxic drugs do not induce a consistent pattern of change in the proliferation and apoptotic indices of individual tumours, but there is a tendency to reduce proliferative activity over all the tumours as a group. It was also found that chemotherapy is capable of modifying the expression of the oncoproteins c-erbB-2 and p53 in a minority of cases of breast cancer, usually resulting in an acquisition of immunoreactive oncoprotein. It is important to be aware of these effects when studying breast carcinomas removed after chemotherapy.
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Chemotherapy is increasingly being used in early breast carcinoma, both as a post-operative adjuvant therapy (Early Breast Cancer Trialists' Group, 1992) and as primary treatment to facilitate breast conservation (Bonadonna et al., 1990) . Accordingly, a growing number of surgical resection specimens of tumours which have been exposed to the effects of cytotoxic drugs are now being received in histopathology laboratories. When assessing the presence or absence of residual tumour, or if attempts at grading a carcinoma are made after chemotherapy, it is necessary for histopathologists to be aware of the changes in morphology of the tumour cells which can occur following such treatment. Previous studies of the morphological effects of chemotherapy on breast cancer have drawn attention to the possibility of confusing residual tumour with reactive histiocytes (Kennedy et al., 1990) . We too have seen similar changes but do not agree that they should be mistaken for benign cells. In this paper, in addition to documenting the tumours' appearances, we report on the effect of prior chemotherapy on the cellular proliferative activity in the carcinomas assessed using two methods: mitotic indices and immunohistochemical staining with the antibody Ki-Sl. The latter recognises a cell cycleassociated antigen and can be used to identify the proliferating compartment within a tumour (Camplejohn et al., 1993) . As a corollary to this we also measured the apoptotic index in the tumour cells and performed immunostaining for bcl-2 protein, which is thought to protect cells from undergoing apoptosis (Wyllie, 1993) . It has also been shown that the expression of certain oncoproteins in vitro is influenced by treatment with cytotoxic drugs (Whelan et al., 1992; Fritsche et al., 1993) . We are interested in investigating this further with particular reference to two oncoproteins whose expression has been extensively studied in breast carcinoma: c-erbB-2 and p53. The presence of both proteins has been associated with a worse prognosis (Paik et al., 1990; Barnes et al., 1993) , and hence it is important to know if their expression can be affected by chemotherapy in vivo. It has been shown that DNA damage induced by UV irradiation can give rise to detectable levels of p53 protein Cattoretti et al. (1992) with the single modification that the sections were heated in a microwave oven (700W) for 10 min before immunostaining. On H&E-stained sections the morphology of the tumour before and after chemotherapy was compared. To measure mitotic and apoptotic indices a minimum of 2,000 cells were assessed and the number of mitoses or apoptoses was counted using hand-held haematology counter. On the needle core biopsies this could often be achieved on one section but, where necessary, sections cut at multiple 30 Sum levels were employed. The indices were then expressed per 1,000 cells. A similar method was used to measure proliferative activity with the Ki-SI antibody, which has been shown to identify a cell cycleassociated nuclear antigen and, if used appropriately, it can be used as a marker of cell proliferation in formalin-fixed tissue (McCormick et al., 1993) . Only strongly staining nuclei were counted in a minimum of 2,000 tumour cells, again giving an index number of stained cells per 1,000. It has previously been shown that assessment of Ki-SI in this manner correlates with cell proliferation as measured by flow cytometry (Camplejohn et al., 1993) and is also an independent prognostic indicator in breast carcinoma (Sampson et al., 1992 
Results
Using the treatment regimens in Table I (Figure la and b) . In a few cases the nuclei were enlarged but hyperchromatic and dense with an irregular, angulated outline (Figure 2a and b) . These changes were seen in both the infiltrating and in situ components of the tumour and in one patient even in malignant cells in the subcapsular sinus of an axillary lymph node (Figure 2c Assessment of cell proliferation was done using mitotic indices and Ki-SI immunohistochemical staining. We found a statistically significant correlation between the two methods in the pretreatment biopsies (r = 0.28; P = 0.01). However, in the post-treatment tumours this correlation was lost (r = 0.02; P = 0.426). The effect of chemotherapy on cell proliferation was variable, with some tumours showing a rise in proliferation indices, others showing a fall and a few cases remaining unchanged. Assessment using both mitotic index and Ki-Sl staining gave broadly similar results over the entire study group (Table VII and Figures 3 and 4) .
As a measure of cell death induced by chemotherapy we assessed the apoptotic index before and after treatment in parallel with immunostaining for the bcl-2 protein. The results are also shown in Table VI correlation of bcl-2 staining with the apoptotic index was found, but an association between the apoptotic index and the mitotic index was apparent (r = 0.26; P = 0.016) in the pretreatment tumours which was not observed following chemotherapy.
Although a similar pattern of changes in cell proliferation and apoptosis emerged from the group of tumours as a whole, individual carcinomas did not always show parallel changes in each of the parameters studied.
Chemotherapy was also found to modify the expression of oncoproteins in the malignant cells. We carried out staining for c-erbB-2 and found that in six tumours there was an acquisition of the protein in previously negative cases ( Figure  6a and b) with an increase in protein expression (from + to Tabie VII Effect of chemotherapy on tumour growth characteritcs (Table VIII) . A similar overall pattern was seen on staining for p53 protein with acquisition of p53 staining in eight tumours (Figure 7a and b) and loss of staining in two cases (Table IX) . There was no correlation between the tumours which showed changes in c-erbB-2 expression and those in which p53 staining was alterd. The (n = 4), those with only residual DCIS (n = 2) and those with only minimal residual invasive disease <5 mm in maximum dimension (n = 3). We compared the pretreatment characteristics of these tumours with the others in the study group who had sizeable residual tumours. There (Brifford et al., 1989) . A more systematic study of the effects of combined tamoxifen and cytotoxic drug treatment on breast carcnoma was caied out by Kennedy et al. (1990) . In 16% of the tumours, cells with a morphology very similar to that described in our cases was seen but differentiation of these cells from a benign histiocytic reaction was stressed. We believe that this is misleing and that the cells observed have frankly malignant features. In our opinion the main rationale for recognising this characteristic cellular appearance is to avoid attributing too high a grade to the tumour when attempting to provide some prognostic information. Indeed the value of either histological or cytological grading following treatment is doubtful. We interpret the changes as degenerative with nuclear enlargement and vacuolation followed by hyperchromasa within the enlarged nuclei. In two patients whose tumours subsequently recurred loally the histological appearances of the recurrece were similar to the primary biopsy sample and did not show any of the altered malignant cells. Thus, the morphological changes appear to be a transient phenomenon related to the administration of the cytotoxic drugs. This has been noted in relation to similar changes in the urothelium (Forni et al., 1964 (Akanuma, 1978 (Kennedy et al., 1989; O'Reilly et al., 1992; Skoog et al., 1992 The mechanism by which cell death, and hence loss of tumour bulk, occurs has been the subject of much recent study. Many cytotoxic agents appear to activate the intracellular pathways which culminate in apoptosis. This is the final common pathway for many processes which are lethal to cells (Searle et al., 1975; Dyson et al., 1986; Eastman, 1990; Lennon et al., 1990; Kyprianou et al., 1991) . However, there is some experimental evidence that cytotoxic drugs may act in a different fashion in higher doses when they cause direct tissue necrosis (Dvyson et al., 1986) . In our cases the overall change in apoptotic indices mirrored the changes in cell proliferation with an increase in apoptoses in approximately one-third of cases but a fall in the numbers of apoptoses in the majority of tumours. No gross areas of tumour necrosis were seen histologically. Rather the site of the tumour clinically was often occupied by hyaline fibrous tissue; this could conceivably represent the aftermath of previous necrosis. We found bcl-2 staining in 26% (7/27) of pretreatment biopsies and no correlation with the apoptotic index. This is in contrast to other studies in which 70-90% of invasive breast carcinomas were found to contain bcl-2 immunoreactivity (Chan et al., 1993a,b; Nathan et al., 1993) . The correlation between bcl-2 reactivity and tumour grade is uncertain : Chan et al. (1993a,b) noted a negative correlation between bcl-2 and the grade of infiltrating ductal carcinomas with only 40% of grade 3 carcinomas staining for bcl-2.
However no correlation with tumour grade was found in a larger study (Nathan et al., 1993) . Chan et al. (1993b) also found a stronger correlation between the apoptotic index and the expression of bcl-2 in tumours with a low mitotic index (<6 mitoses per 1,000 cells). We postulate that the lower index of bcl-2 staining seen in our cases is related to the fact that they are mainly high-grade tumours with high mitotic indices (mean eight mitoses per 1,000 cells). Indeed, in a multiple regression analysis of our group of tumours apoptosis was correlated with the mitotic index and not with bcl-2 staining. A similar correlation of the apoptotic index with the mitotic index was noted by Chan et al. (1993a) . Thus, these rapidly proliferating tumours appear to be in a 'high turnover state' in which there is an increased chance of apoptosis amongst proliferating cells. It would appear that the proliferative stimulus, driving the cells into a state in which they are vulnxrable to apoptosis, overrides the protective effect of bcl-2 against apoptosis (Dive et al., 1992) .
Changes in oncoprotein expression after chemotherapy
The changes that were observed in the expression of the oncoproteins c-erbB-2 and p53 after chemotherapy are of interest. Experiments in vitro have shown that treatment of cells grown in cell culture with vincristine can induce the expression of c-erbB-2 on previously negative cells (Whelan et al., 1992) . This is the first evidence that, at least in a proportion of cases, the same effect can be demonstrated in vivo following treatment with combination chemotherapy. The c-erbB-2 protein is thought to behave as a constitutively active growth factor receptor, and expression of the oncoprotein has been shown to correlate with cell proliferation as measured by the thymidine labelling index (Barnes et al., 1991) . The emergence of cells bearing this oncoprotein after chemotherapy is consistent with the early recovery of a cell population that possesses a growth advantage and is in keeping with the Gompertzian model of increased cell proliferation in smaller tumours.
Currently p53 protein is thought to act as a 'genomic guardian' which arrests cells with DNA mutations at the GI-S checkpoint and prevents cell replication with the propagation of the mutation (Lane, 1992; Vogelstein & Kinzler, 1992) . Treatment of cells in vitro with irradiation, ultraviolet light and radiomimetic drugs has been shown to induce accumulation of p53 in a response to DNA damage (Wynford-Thomas, 1992; Fritsche et al., 1993; Hall et al., 1993) .
Similar effects have been found in the skin in vivo following UV exposure . Initially the detection of p53 protein by immunohistochemistry was thought to be possible only when abnormally stabilised mutant protein was present. More recent reports have emphasised that accumulation of even wild-type p53 can also allow its immunohistochemical detection but that the function of the protein may still be abnormal (Walker et al., 1991 Thus, this is suggested to be further support for the role of p53 in DNA repair in a human tumour in vivo.
